Back

LDL cholesterol target attainment in a representative German cohort of high- and very-high-CV risk patients with statin intolerance: a simulation study

28 August 2023 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention: lipids (5) Drug therapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Julius Katzmann

University Hospital Leipzig, Leipzig (Germany)

8 More presentations in this session

Presentation thumbnail
Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
Early diagnosis and treatments in childhood are associated with better prognosis in patients with familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
L-shaped association of lipoprotein(a) on long-term bleeding risk in patients with coronary heart disease: insight from a multicenter cohort in Asia
Doctor P. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Survey on lipid management in cardiovascular primary prevention: do physicians follow the guidelines?
Professor M. Alami (Casablanca, MA)
Abstract Slides Video
Presentation thumbnail
Remnant cholesterol predicts major cardiovascular events in cardiovascular disease patients with NAFLD
Doctor B. Larcher (Feldkirch, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention: lipids (5)

The Event

Event poster

ESC Congress 2023

28 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation
thumbnail
Congress Presentation
Triple oral lipid-lowering treatment pathway and associated outcomes in high- and very high-cv risk patients: a simulation using the SANTORINI study cohort
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources